-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
High body mass index (BMI) is related to the poor clinical prognosis of patients with early breast cancer (BC), and its negative impact may be mediated by hyperglycemia/ diabetes .
Breast cancer diabetes
Researchers such as Francesca conducted a retrospective study to explore the non-recurrence of baseline BMI or blood glucose levels in patients with stage I-III HER2+BC undergoing surgical resection and undergoing standard diagnosis and treatment , trastuzumab-adjuvant biochemotherapy The impact of survival period (RFS) and overall survival (OS).
Diagnosis and treatment
The study recruited a total of 505 patients.
BMI critical value is 27.
The impact of BMI and blood glucose on OS and RFS in all patients
The impact of BMI and blood glucose on OS and RFS in all patientsIn a multivariate analysis, in the entire patient population, higher BMI was associated with poor RFS (hazard ratio 2.
In the entire patient population, higher BMI is associated with poor RFS and poor OS .
The effect of BMI and blood glucose on RFS of different hormone receptor subgroups
The effect of BMI and blood glucose on RFS of different hormone receptor subgroupsIn contrast, hyperglycemia at baseline (≥109 mg/dl) was only significantly correlated with worsening RFS in HR+/HER2+BC patients in multivariate analysis (hazard ratio 2.
In conclusion, for early HR-/HER2+BC patients receiving trastuzumab adjuvant biochemotherapy, high BMI is associated with poor clinical prognosis, while for HR+/HER2+BC patients, baseline hyperglycemia may be a poor RFS Predictor .
For early HR-/HER2+BC patients receiving trastuzumab adjuvant biochemotherapy, high BMI is associated with poor clinical prognosis, while for HR+/HER2+BC patients, baseline hyperglycemia may be a predictor of poor RFS factor
Original source:
Original source:Ligorio Francesca,Zambelli Luca,Bottiglieri Achille et al.
org/10.
1177/17588359211006960">Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients
in this message
